I made illustration of Corona virus today. ? I hope scientists and doctors can find a cure soon and I wish everyone who was affected to get well and recover soon! hashtag#sciart
New Members to Add Experience to Board of Directors
ROCKVILLE, MARYLAND, February 12, 2020 – BioHealth Innovation, Inc. (BHI) announced that its Board of Directors unanimously has approved the appointments of six new board members:
- Sean Augerson, Vice President, Head of Operations Americas and APAC, QIAGEN
- Peter Briskman, Executive Managing Director, JLL
- Juergen Klenk, Ph.D., Principal, Deloitte
- Dr. Jay Perman, MD, Chancellor, University System of Maryland
- Aaron Ren, Head of Business Development and Operations, Viela Bio
- Tracey Vetterick, Vice President and COO, Oncology R&D, AstraZeneca
“I am privileged to welcome these new members to our board,” said Richard Bendis, BHI President and CEO. “The addition of their leadership experience in the BioHealth Capital Region and beyond ensures in BHI’s ability to have our finger on the pulse of innovation and fresh viewpoints. I also would like to thank Rip Ballou of GSK, Robert Caret of the University System of Maryland, Doug Liu of QIAGEN, Ashish Kulkarni, of Avantor, and Beth Meagher of Deloitte Consulting LLP for their many years of service on our Board of Directors.
The first BioTalk of 2020 kicks off with Andrea Alms, MS, MBA, Co-Fund Manager of BioHealth Capital Fund as she discusses her background, the world of Angel Investment, and her vision for the Fund
Click here to listen to the podcast.
Andrea Alms is the co-fund manager of BioHealth Capital Fund. The BioHealth Capital Fund is a venture capital early stage investment fund created by the BioHealth Innovation (“BHI”), located in Rockville, MD, the center of the BioHealth Capital Region. BHI manages a for profit subsidiary BioHealth Innovation Management (BHIM) which owns equity in 27 of the 108 client companies of BHI and has had 3 exits. Our lead investor is Alexandria Real Estate Equities; and, our reference is Joel Marcus. Andrea is recognized for her abilities in guiding venture capital, private equity, mergers and acquisitions (M&A), and other transactions involving early stage companies. Andrea assists limited partners, general partners, investors, and entrepreneurs as they create, build, and buy or sell businesses, primarily in BioHealth, healthcare, technology, and digital health products industries.
BHI is assisting one of its client companies, Medimaps) seeking US sales, customer and marketing support (see position descriptions). Medimaps is an exciting start-up company that is prepared to grow exponentially in the next phase and is looking for dynamic, experienced, and flexible people interested in being a part of this journey. The company is seeking someone who would like to be a critical player to the success of this exciting medtech company. Medimaps Group (MG) is the leader in bone and tissue microarchitecture software analytics. Its proven technology helps doctors make improved clinical decisions for the patients. Over the past several years, Medimaps has developed innovative technology, demonstrated and published clinical efficacy, received regulatory approval, built its network of distributors and partners around the world, and gained worldwide acceptance as standards of care for osteoporosis fracture risk assessment. Medimaps’ premier product, Trabecular Bone Score (TBS) is sold in more than 60 countries. MG currently has 20+ employees between our Headquarters in Geneva Switzerland, our R&D in Bordeaux, France, and our General Office in the US which is expanding. To apply for either position, please send your resume, cover letter, and three professional references to BHI@BIoHealthInnovation.org
Gain Visibility for Your BioHealth Company – and $10,000.
Prior winners: Sonavex, LifeSprout, Galen Robotics, Floreo
Register now for the eighth annual Public Health Research at Maryland day on Tuesday April 7. We’ll delve into the latest research focused on improving the health and well-being of diverse communities across Maryland, the nation and the world. This year’s theme, Our 2020 Vision for Healthy People 2030, highlights the release of the new Healthy People Objectives for 2030 on March 31.
SOMERSET, N.J. & GOSSELIES, Belgium–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
Herndon, VA, Feb. 04, 2020 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) today announced the appointment of Greg Feldmann, President of Skyline Capital Strategies, an affiliate of Woods Rogers, PLC, as CIT GAP Funds Venture Partner. CIT GAP Funds and affiliated Virginia Founder’s Fund (VFF) are committed to identifying viable start-up investment opportunities in all parts of the Commonwealth. As a Venture Partner, Feldmann will provide outreach services to cultivate new and existing sources of deal flow and early-stage investment capital in the Roanoke-Blacksburg corridor, Southside Virginia, Lynchburg and Far Southwest Virginia.“CIT recognizes the wealth of technology and strong entrepreneurial spirit of the Roanoke-Blacksburg corridor and adjacent geographies,” said Tom Weithman, Managing Director of CIT GAP Funds. “A critical part of harnessing those assets to create economic development benefit for the Commonwealth turns on mobilizing capital to drive development of emerging companies.
Image: https://www.streetinsider.com
Merck & Co. Inc. unveiled plans Wednesday to spin off products from its women’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company.
Going forward, Merck (NYSE: MRK) will focus on its oncology, vaccines, hospital medicine and animal health segments.
Merck expects the spinoff to be completed by the first half of 2021. The pharmaceutical giant anticipates cost savings of more than $1.5 billion — primarily in areas such as manufacturing and sales staff costs — by 2024. In addition, Merck said by continuing to increase investments in its key growth drivers and pipeline assets, it is targeting operating margins to grow to more than 40% in 2024.
Its potential 1.7 million-square-foot campus in South San Francisco matches the biotech industry’s growth.